YUVIWEL (navepegritide) — Regulatory decision
Q4 2026
Marketing Authorisation Application remains under review by the European Medicines Agency, with a decision anticipated in the fourth quarter of 2026.Source filing
ASND biotech catalysts & pipeline
ASCENDIS PHARMA A · Data as of 2026-09-08